Grants paid by Foundation for Angelman Syndrome Therapeutics
EIN 26-3160079 · Austin, TX · Form 990, Schedule I · NTEE H12
Foundation for Angelman Syndrome Therapeutics of Austin, TX (EIN 26-3160079) reported 36 grants paid totaling $16,662,546 to 13 recipients in tax years 2020–2024, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$16,662,546
36 grants
Recipients
13
distinct organizations
Tax years
2020–2024
4 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2020 | 5 | $2,368,927 | — |
| 2022 | 4 | $800,071 | — |
| 2023 | 17 | $5,572,273 | — |
| 2024 | 10 | $7,921,275 | — |
Top recipients
The 13 recipients receiving the most from Foundation for Angelman Syndrome Therapeutics, by grants paid, out of 13 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| University of Pennsylvania 23-1352685 | A | Philadelphia, PA | 3 | $7,829,245 | 2024 |
| Yale University 06-0646973 | A | New Haven, CT | 4 | $2,267,672 | 2023 |
| Rush University Medical Center 36-2174823 | A | Chicago, IL | 2 | $1,608,100 | 2024 |
| Boston Children's Hospital 04-2774441 | A | Boston, MA | 2 | $929,075 | 2024 |
| Regents of the University of California Davis 94-6036494 | A | Davis, CA | 3 | $645,636 | 2024 |
| North Carolina State University 56-6000756 | A | Raleigh, NC | 5 | $586,809 | 2023 |
| Texas A&m University 74-6000541 | A | College Station, TX | 3 | $582,444 | 2023 |
| Brown University 05-0258809 | A | Providence, RI | 4 | $445,000 | 2024 |
| Duke University 56-0532129 | A | Charlotte, NC | 3 | $402,385 | 2024 |
| Children's Research Institute 52-1654453 | A | Washington, DC | 2 | $387,446 | 2024 |
| Keck Graduate Institute of Applied Life Sciences 95-4625327 | A | Claremont, CA | 2 | $375,000 | 2024 |
| The Regents of the University of California San Francisco 94-6036493 | A | San Francisco, CA | 2 | $304,413 | 2024 |
| North Carolina State University 27-0080644 | A | Winston Salem, NC | 1 | $299,321 | 2020 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 36 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | University of Pennsylvania Philadelphia, PA | A | $5,860,869 | paid | UPENN 2023: RESEARCH, COLLABORATION & LICENSE AGREEMENT | 202532729349301973 |
| 2024 | Boston Children's Hospital Boston, MA | A | $470,957 | paid | FT2022-006: ABOM - NATURAL HISTORY STUDY | 202532729349301973 |
| 2024 | Rush University Medical Center Chicago, IL | A | $320,500 | paid | RUSH COE | 202532729349301973 |
| 2024 | Duke University Charlotte, NC | A | $317,848 | paid | FT2018-005 AMENDED: GPIC-COMM | 202532729349301973 |
| 2024 | Regents of the University of California Davis Davis, CA | A | $274,044 | paid | FT2022-007: GASTROINTESTINAL BIOMARKERS IN PRECLINICAL MODELS OF ANGELMAN SYNDROME | 202532729349301973 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | A | $210,711 | paid | FT2023-002: DEVELOPING A CRISPRA THERAPY FOR THE CLASSI/II DELETION GENOTYPE OF ANGELMAN SYNDROME | 202532729349301973 |
| 2024 | Brown University Providence, RI | A | $150,000 | paid | FT2022-005: DEVELOPMENT OF BDNF POTENTIATING THERAPEUTICS FOR MOTOR AND COGNITIVE DYSFUNCTION IN AS | 202532729349301973 |
| 2024 | Children's Research Institute Washington, DC | A | $140,846 | paid | FT2022-003: PEAK ALPHA FREQUENCY AS AN EEG BIOMARKER FOR ANGELMAN SYNDROME | 202532729349301973 |
| 2024 | Keck Graduate Institute of Applied Life Sciences Claremont, CA | A | $125,000 | paid | FT2022-002: TARGETING ANGELMAN SYNDROME THERAPEUTICS TO THE BRAIN UTILIZING NOVEL CELL PENETRATING PEPTIDES | 202532729349301973 |
| 2024 | Brown University Providence, RI | A | $50,500 | paid | PD2023-001: POSTDOCTORAL FELLOWSHIP PROGRAM | 202532729349301973 |
| 2023 | University of Pennsylvania Philadelphia, PA | A | $1,853,255 | paid | UPENN 2023: RESEARCH, COLLABORATION & LICENSE AGREEMENT | 202423209349327812 |
| 2023 | Rush University Medical Center Chicago, IL | A | $1,287,600 | paid | RUSH COE | 202423209349327812 |
| 2023 | Boston Children's Hospital Boston, MA | A | $458,118 | paid | FT2022-006: ABOM - NATURAL HISTORY STUDY | 202423209349327812 |
| 2023 | Texas A&m University College Station, TX | A | $267,142 | paid | FT2019-008: TRANSLATIONAL RESEARCH IN PIG MODEL OF AS | 202423209349327812 |
| 2023 | Yale University New Haven, CT | A | $257,475 | paid | FT2020-006: GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A | 202423209349327812 |
| 2023 | Keck Graduate Institute of Applied Life Sciences Claremont, CA | A | $250,000 | paid | FT2022-002: TARGETING ANGELMAN SYNDROME THERAPEUTICS TO THE BRAIN UTILIZING NOVEL CELL PENETRATING PEPTIDES | 202423209349327812 |
| 2023 | Children's Research Institute Washington, DC | A | $246,600 | paid | FT2022-003: PEAK ALPHA FREQUENCY AS AN EEG BIOMARKER FOR ANGELMAN SYNDROME | 202423209349327812 |
| 2023 | Brown University Providence, RI | A | $194,000 | paid | FT2022-005: DEVELOPMENT OF BDNF POTENTIATING THERAPEUTICS FOR MOTOR AND COGNITIVE DYSFUNCTION IN AS | 202423209349327812 |
| 2023 | North Carolina State University Raleigh, NC | A | $178,887 | paid | FT2022-001: MICROPROBE-INTEGRATED HUMAN ORGANOID ARRAYS TO STUDY AS GENOTYPES AND THERAPEUTICS | 202423209349327812 |
| 2023 | North Carolina State University Raleigh, NC | A | $161,647 | paid | FT2021-002: ISOGENICALLY CONTROLLED HUMAN CELL LINES TARGETING ABERRANT IMPRINTING GENOTYPES AND A NEW REPORTER CELL LINE. | 202423209349327812 |
| 2023 | The Regents of the University of California San Francisco San Francisco, CA | A | $93,702 | paid | FT2023-002: DEVELOPING A CRISPRA THERAPY FOR THE CLASSI/II DELETION GENOTYPE OF ANGELMAN SYNDROME | 202423209349327812 |
| 2023 | Duke University Charlotte, NC | A | $75,445 | paid | FT2018-005 AMENDED: GPIC-COMM | 202423209349327812 |
| 2023 | Regents of the University of California Davis Davis, CA | A | $75,000 | paid | FT2022-007: GASTROINTESTINAL BIOMARKERS IN PRECLINICAL MODELS OF ANGELMAN SYNDROME | 202423209349327812 |
| 2023 | Brown University Providence, RI | A | $50,500 | paid | PD2023-001: POSTDOCTORAL FELLOWSHIP PROGRAM | 202423209349327812 |
| 2023 | Yale University New Haven, CT | A | $50,500 | paid | PD2022-001: POSTDOCTORAL FELLOWSHIP PROGRAM | 202423209349327812 |
| 2023 | North Carolina State University Raleigh, NC | A | $43,087 | paid | FT2022-008: STEM CELL LINE IN-VITRO INFRASTRUCTURE CREATED AT NCSU FOR INDUSTRY AND ACADEMIC SUPPORT | 202423209349327812 |
| 2023 | North Carolina State University Raleigh, NC | A | $29,315 | paid | RADAR 2023-2137 | 202423209349327812 |
| 2022 | Texas A&m University College Station, TX | A | $277,778 | paid | TRANSLATIONAL RESEARCH IN PIG MODEL OF AS | 202323199349331737 |
| 2022 | Yale University New Haven, CT | A | $233,299 | paid | GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A | 202323199349331737 |
| 2022 | North Carolina State University Raleigh, NC | A | $173,873 | paid | BANDODKAR LAB HUMAN ORGANOID ARRAYS TO STUDY AS | 202323199349331737 |
| 2022 | University of Pennsylvania Philadelphia, PA | A | $115,121 | paid | A. THE UBE3A ANTISENSE TRANSCRIPT (UBE3A-AS) IS A LONG NON-CODING MRNA THAT SILENCES EXPRESSION OF THE PATERNAL UBE3A GENE IN NEURONS. INTERRUPTION OF THIS IMPRINTING PHENOMENON CAN BE DONE THROUGH ASOS, CRISPR-GRNA OR OTHER TECHNOLOGIES LIKE MICRORNA (MIRNA). THIS PROJECT IS AIMING TO DEVELOP A STRATEGY TO SUPPRESS THE UBE3A-AS IN THE MOUSE MODEL OF AS USING MIRNAS. ADVANTAGES TO MIRNA ARE THAT THEY ARE SUBJECT TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION, WHICH CAN HELP CIRCUMVENT ISSUES RELATED TO OVEREXPRESSION OF EXOGENOUS GENETIC MATERIAL (WITH UBE3A REPLACEMENT), AND THE NEED FOR REPEATED REDOSING (WITH ASOS). MIRNA IS THOUGHT TO BE ADVANTAGEOUS OVER SHRNA DUE TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION COMPARED TO OVEREXPRESSION YOU COULD GET WITH SHRNA. | 202323199349331737 |
| 2020 | Yale University New Haven, CT | A | $1,726,398 | paid | GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A | 202132889349302688 |
| 2020 | North Carolina State University Winston Salem, NC | A | $299,321 | paid | A HUMAN PLATFORM TO EFFICIENTLY STUDY CLASS 1 DELETED GENES | 202132889349302688 |
| 2020 | University of California Davis Davis, CA | A | $296,592 | paid | TRANSLATIONAL ANALYSIS OF GAIT AS A PRIMARY OUTCOME MEASURE IN ANGELMAN SYNDROME | 202132889349302688 |
| 2020 | Texas A&m University College Station, TX | A | $37,524 | paid | TRANSLATIONAL RESEARCH IN PIG MODEL OF AS | 202132889349302688 |
| 2020 | Duke University Center for Health Management Durham, NC | A | $9,092 | paid | OUTCOME MEASURE STUDY | 202132889349302688 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.2 | 202532729349301973 |
| 990 | 2023 | 2023-12-31 | not stated | 2023v5.1 | 202423209349327812 |
| 990 | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202323199349331737 |
| 990 | 2020 | 2020-12-31 | not stated | 2020v4.1 | 202132889349302688 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/263160079.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.